Jeffrey Whitten

Jeffrey Whitten is a highly experienced professional in the biotechnology and pharmaceutical sectors, currently serving as Chief Scientific Officer at Algen Biotechnologies since April 2022. Prior to this role, Jeffrey held the position of CEO at Paris Therapeutics from January 2014 to February 2022. Additionally, Jeffrey was the Senior Vice President of Preclinical and CMC Development at TP Therapeutics from November 2015 to June 2019, and served as Vice President of Chemistry at CalcIiMedica from July 2008 to November 2013. Earlier in their career, Jeffrey worked as Vice President of Research at Cylene Pharmaceuticals from 2005 to 2008.